SynAct Pharma’s Board of Directors has established an R&D Committee. It is a preparatory organ within the Board with the main duties to:
(a) review and endorse resolutions pertaining to matters regarding research and development, proposed by management, to be adopted by the Board; and
(b) act as scientific advisors to the management of SynAct Pharma.

The R&D Committee is composed of Terje Kalland (chairman), and Uli Hacksell.